News

Novo Nordisk: The Market Has Lost Its Mind
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Zacks.com on MSN9h
LLY Stock Sinks Despite Q2 Earnings Beat as Obesity Pill Disappoints
LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.
sharewise3d
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
The second-quarter earnings season for the drug and biotech sector accelerated last week and will be in full swing this week, ...
Novo Nordisk: More Pain On The Horizon
Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a ...
The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk
Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...
Novo Nordisk Stock Hits New 52-Week Low Amid Profit Warning: What Investors Need To Know
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...